Nemolizumab Therapeutic Cheat Sheet
Atopic dermatitis and prurigo nodularis are chronic, life-altering diseases with a common feature of debilitating pruritus that significantly impacts our patients’ qualities of life. For those with resistant and extensive disease, dermatologists now have nemolizumab in our armamentarium, the first FDA approved IL-31 inhibitor. We continue our series, Therapeutic Cheat Sheet, with a closer look a …
Atopic dermatitis and prurigo nodularis are chronic, life-altering diseases with a common feature of debilitating pruritus that significantly impacts our patients’ qualities of life. For those with resistant and extensive disease, dermatologists now have nemolizumab in our armamentarium, the first FDA approved IL-31 inhibitor. We continue our series, Therapeutic Cheat Sheet, with a closer look a … 
As dermatologists, we recognize that chronic itch is a complex and often debilitating condition that significantly impacts our patients' quality of life, affecting their physical health, mental well-being, and daily activities. Chronic itch can be especially challenging to diagnose and treat, particularly in patients with skin of color, who may experience unique clinical manifestations and complic … 